Thea Pharma Inc launches preservative-free latanoprost ophthalmic solution in the U.S.

Thea Pharma Inc has launched Iyuzeh (latanoprost ophthalmic solution) 0.005% to the U.S. market, according to a press release.

This preservative-free latanoprost, previously launched over a decade ago and used by around 1.5 million patients monthly across 46 countries under the brand Monoprost, is now available in the U.S. Iyuzeh is the sole preservative-free latanoprost for patients with primary open-angle glaucoma and ocular hypertension in the U.S.

Clinical trials have shown that Iyuzeh effectively lowers intraocular pressure by 3–8 mmHg in patients with primary open-angle glaucoma or ocular hypertension, compared to 4–8 mmHg with Xalatan.

“With the launch of Iyuzeh in the U.S., Thea is responding to an important unmet need in the treatment landscape. Iyuzeh brings similar efficacy of traditional latanoprost, formulated without preservatives, to help eye care providers confidently address their treatment goals of lowering intraocular pressure for people with [primary open-angle glaucoma and ocular hypertension],” said Susan Benton, President of Thea Pharma Inc. “We are thrilled to introduce Iyuzeh and provide clinicians with an important new treatment option for their patients.”

Read the full press release here.